kidney disease

MA strategy deal block push come together form
Biotech

Amicus pays Dimerix $30M for late-phase rare kidney disease drug

Amicus has bagged U.S. rights to the phase 3 prospect DMX-200, establishing it as a challenger to Travere Therapeutics in a rare kidney disease.
Nick Paul Taylor May 1, 2025 10:59am
Graphic image of two hands shaking with employeesexecutives on the forearms of each shaking hand

Novartis pays $800M to buy Regulus for phase 3-ready kidney drug

Apr 30, 2025 9:30am
Ship sailing through stormy seas

Arbor sails into rocky gene editing waters with $74M

Mar 18, 2025 6:30am
Kidneys brightly lit

Arrowhead shares ‘select’ data for RNAi asset in kidney trial

Mar 10, 2025 11:55am
Doctor holding diagram of kidneys

BioCity's ETA antagonist reduces proteinuria in ph. 2 DKD trial

Feb 25, 2025 4:45am
long shot miss basketball hoop fail shoot

Novo fails trial, linking obesity asset to psychiatric effects

Feb 5, 2025 7:39am